Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Deckers Outdoor Corp (DECK) vs Novo Nordisk A/S (NVO) Price & Performance

Deckers Outdoor CorpTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Deckers Outdoor Corp vs Novo Nordisk A/S — how do they compare? Deckers Outdoor Corp trades at $106.98 (market cap $14.97B), while Novo Nordisk A/S trades at $49.22 (market cap $218.15B). The key difference: Novo Nordisk A/S is far larger — about 14.6× Deckers Outdoor Corp's market cap, and Novo Nordisk A/S pays a 3.66% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals.

DECKNVO
Market Cap
$14.97B$218.15B
Sector
Consumer CyclicalHealth
52-Week High
$123.91$71.70
52-Week Low
$79.54$35.29
Enterprise Value
$13.44B$237.11B
Dividend Yield
3.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Deckers Outdoor Corp

No Aura AI signal available yet.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.

Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Deckers Outdoor Corp

Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.

Read more on DECK

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO